Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
The purpose of this conversion therapy study is to evaluate the safety and efficacy of neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally advanced NSCLC.
NSCLC, Stage III
DRUG: Tislelizumab|DRUG: Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)|DRUG: Carboplatin
Resectability rate, Resectability rate is defined as the percentage of patients who were able to undergo surgery after neoadjuvant therapy., At time of surgery
Major pathological response rate (MPR), MPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy., At time of surgery|Pathology complete response rate(pCR), pCR rate is defined as the percentage of participants lacking of evidence of viable tumor cells in the pathological examination of resected specimens., At time of surgery|R0 Resection rate, R0 Resection rate is defined as the percentage of patients who were able to undergo R0 Resection surgery after neoadjuvant therapy., At time of surgery|Perioperative G3-4 Adverse Events (AEs), The number of participants experiencing an perioperative G3-4 AE will be assessed., Up to 1 month post surgery
The purpose of this conversion therapy study is to evaluate the safety and efficacy of neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally advanced NSCLC.